within Pharmacolibrary.Drugs.ATC.A;

model A03AB02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 1.1333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 1800,            
    Vdp             = 0.0021000000000000003,
    k12             = 1.2,
    k21             = 1.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Glycopyrronium bromide is a synthetic antimuscarinic (anticholinergic) agent used primarily to treat gastrointestinal disorders such as peptic ulcers, drooling (sialorrhea) in neurological disorders, and as a preoperative medication to reduce salivary and respiratory secretions. It is also used as an inhaled bronchodilator for chronic obstructive pulmonary disease (COPD). Glycopyrronium bromide is approved and widely used in clinical practice today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Chabicovsky, M, et al., &amp; Abels, C (2019). Pharmacology, toxicology and clinical safety of glycopyrrolate. <i>Toxicology and applied pharmacology</i> 370 154–169. DOI:<a href=\"https://doi.org/10.1016/j.taap.2019.03.016\">10.1016/j.taap.2019.03.016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30905688/\">https://pubmed.ncbi.nlm.nih.gov/30905688</a></p></li><li><p>Sechaud, R, et al., &amp; Hou, J (2016). Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 41(6) 723–731. DOI:<a href=\"https://doi.org/10.1007/s13318-015-0300-7\">10.1007/s13318-015-0300-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26428357/\">https://pubmed.ncbi.nlm.nih.gov/26428357</a></p></li><li><p>Rautakorpi, P, et al., &amp; Kanto, J (1998). Pharmacokinetics and oral bioavailability of glycopyrrolate in children. <i>Pharmacology &amp; toxicology</i> 83(3) 132–134. DOI:<a href=\"https://doi.org/10.1111/j.1600-0773.1998.tb01456.x\">10.1111/j.1600-0773.1998.tb01456.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9783332/\">https://pubmed.ncbi.nlm.nih.gov/9783332</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AB02;
